Literature DB >> 12507537

Antimuscarinics and the overactive detrusor--which is the main mechanism of action?

K-E Andersson1, M Yoshida.   

Abstract

Contraction of the bladder, voluntary or involuntary, involves stimulation of the muscarinic receptors on the detrusor by acetylcholine, released from activated cholinergic nerves. Antimuscarinics are the drugs of choice for treatment of detrusor overactivity and the overactive bladder (OAB) syndrome. However, antimuscarinics at clinically recommended doses have little effect on voiding contractions, and may act mainly during the bladder storage phase, during which there is normally no parasympathetic outflow from the spinal cord. Supporting this, antimuscarinics have been shown to reduce bladder tone during storage, and to increase cystometric bladder capacity. A basal release of acetylcholine from non-neuronal (urothelial) as well as neuronal sources has been demonstrated in isolated human detrusor muscle. It is suggested that this release, which is increased by stretching the muscle and in the aging bladder, contributes to detrusor overactivity and OAB by eventually increasing bladder afferent activity during storage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12507537     DOI: 10.1016/s0302-2838(02)00540-7

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  59 in total

Review 1.  [The ice water test and bladder cooling reflex. Physiology, pathophysiology and clinical importance].

Authors:  T Hüsch; T Neuerburg; A Reitz; A Haferkamp
Journal:  Urologe A       Date:  2016-04       Impact factor: 0.639

Review 2.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

3.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

4.  Anti-muscarinic drugs increase rectal compliance and exacerbate constipation in chronic spinal cord injury : Anti-muscarinic drug effect on neurogenic bowel.

Authors:  Abhilash Paily; Guiseppe Preziosi; Prateesh Trivedi; Anton Emmanuel
Journal:  Spinal Cord       Date:  2019-02-25       Impact factor: 2.772

5.  Anticholinergics and central nervous system effects: are we confused?

Authors:  David R Staskin; Edward Zoltan
Journal:  Rev Urol       Date:  2007

6.  Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue.

Authors:  Melinda Wuest; Birgit Eichhorn; Manfred Braeter; Gerhard Strugala; Martin C Michel; Ursula Ravens
Journal:  Pflugers Arch       Date:  2007-12-21       Impact factor: 3.657

7.  Triple therapy in refractory detrusor overactivity: a preliminary study.

Authors:  Ricardo Natalin; Leonardo Oliveira Reis; Cristiano Alpendre; Lia Y Ikari; Alessandro Prudente; Carlos A L D'Ancona
Journal:  World J Urol       Date:  2009-03-18       Impact factor: 4.226

8.  In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats.

Authors:  Takanobu Yamazaki; Yukiko Muraki; Tsuyoshi Anraku
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-08-05       Impact factor: 3.000

9.  Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms?

Authors:  Maya Basu; Aswini Balachandran; Jonathan Duckett
Journal:  Int Urogynecol J       Date:  2015-08-19       Impact factor: 2.894

10.  Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability.

Authors:  Tanya Davis; Iryna Makovey; Michael L Guralnick; R Corey O'Connor
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.